Pituitary gland adenoma

Summary

Pituitary gland adenoma (MONDO:0006373) is a cancer (an umbrella term covering 9 Mondo subtypes) with 6 cohort genes (4 GWAS associations across 1 studies; 1 CIViC-evidence somatic driver) and 79 clinical trials. Top therapeutic interventions include cabergoline, sevoflurane, and aminolevulinic acid.

At a glance

• Classification: Cancer
• Umbrella term: 9 Mondo subtypes
• Cohort genes: 6
• GWAS associations: 4
• Clinical trials: 79

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pituitary gland adenoma
Mondo ID	MONDO:0006373
EFO	EFO:1000478
Orphanet	99408
DOID	DOID:3829
NCIT	C3329
SNOMED CT	254956000
UMLS	C0032000
MedGen	45933
GARD	0019680
MedDRA	10035079
Anatomy (UBERON)	UBERON:0000007
Is cancer (heuristic)	yes

Also known as: adenoma of pituitary · adenoma of pituitary gland · adenoma of the pituitary · adenoma of the pituitary gland · adenoma, anterior lobe pituitary gland, benign · pituitary adenoma · pituitary gland adenoma · PTAD

Data availability: 4 GWAS associations (1 study) · 4 cell lines.

Disease family

An umbrella term covering 9 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › adenoma › pituitary gland adenoma

Related subtypes (30): villous adenoma, breast adenoma, minor vestibular glands adenoma, cystadenoma, sebaceous adenoma, renal adenoma, prostatic adenoma, papillary adenoma, Bartholin gland adenoma, mixed cell adenoma, lung adenoma, middle ear adenoma, oncocytic adenoma, clear cell adenoma, lipoadenoma, water-clear cell adenoma, vaginal adenoma, microcystic adenoma, rete testis adenoma, adrenal cortex adenoma, follicular thyroid adenoma, ovarian adenoma benign, digestive system adenoma, mixed somatotroph-lactotroph pituitary gland adenoma, parathyroid gland adenoma, hepatocellular adenoma, adenoma of pancreas, sweat gland adenoma, tubular adenoma, tubulovillous adenoma

Subtypes (9): functioning pituitary gland adenoma, pituitary gland mixed eosinophil-basophil adenoma, ACTH-producing pituitary gland adenoma, growth hormone-producing pituitary gland adenoma, pituitary gland acidophil adenoma, pituitary gland basophil adenoma, chromophobe adenoma, familial isolated pituitary adenoma, non-functioning pituitary adenoma

Genetics & variants

GWAS landscape

4 GWAS associations across 1 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs2359536	2e-10	MIR4675 - NEBL	G	1.44
rs10763170	7e-10	PCDH15	A	1.28
rs17083838	2e-08	CDK8	A	1.37
rs1337875	6e-06	TRIM58 - OR2W3	G	1.37

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST002940	Ye Z	2015	771	2,788	Common variants at 10p12.31, 10q21.1 and 13q12.13 are associated with sporadic pituitary adenoma.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	4

MAF distribution

Bucket	Variants
common (>=0.05)	4
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	2
intergenic_variant	2

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs2359536	10	20610679	T>A,C	0.082	intron_variant	MIR4675 - NEBL	2e-10	Tier 4: intronic/intergenic
rs10763170	10	55017264	T>A,C	0.201	intergenic_variant	PCDH15	7e-10	Tier 4: intronic/intergenic
rs17083838	13	26336975	G>A,T	0.104	intron_variant	CDK8	2e-08	Tier 4: intronic/intergenic
rs1337875	1	247895248	G>A,C	0.05	intergenic_variant	TRIM58 - OR2W3	6e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
RNF6	LoF	COADREAD

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
RNF6	Orphanet:99977	Squamous cell carcinoma of the esophagus
PCDH15	Orphanet:231169	Usher syndrome type 1
PCDH15	Orphanet:90636	Rare autosomal recessive non-syndromic sensorineural deafness type DFNB
CDK8	Orphanet:528084	Non-specific syndromic intellectual disability

Cohort genes → proteins

6 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	6

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RNF6	HGNC:10069	ENSG00000127870	Q9Y252	E3 ubiquitin-protein ligase RNF6	gwas
WASF3	HGNC:12734	ENSG00000132970	Q9UPY6	Actin-binding protein WASF3	gwas
PCDH15	HGNC:14674	ENSG00000150275	Q96QU1	Protocadherin-15	gwas
NEBL	HGNC:16932	ENSG00000078114	O76041	Nebulette	gwas
CDK8	HGNC:1779	ENSG00000132964	P49336	Cyclin-dependent kinase 8	gwas
MIR4675	HGNC:41619	ENSG00000265372		microRNA 4675	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RNF6	E3 ubiquitin-protein ligase RNF6	E3 ubiquitin-protein ligase mediating ‘Lys-48’-linked polyubiquitination of LIMK1 and its subsequent targeting to the proteasome for degradation.
WASF3	Actin-binding protein WASF3	Downstream effector molecules involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton.
PCDH15	Protocadherin-15	Calcium-dependent cell-adhesion protein.
NEBL	Nebulette	Binds to actin and plays an important role in the assembly of the Z-disk.
CDK8	Cyclin-dependent kinase 8	Component of the Mediator complex, a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes.

Protein-family classification

Druggable: 1 · Difficult: 2 · Unknown: 3 · Druggable fraction: 0.17

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	4.6×	0.601
Scaffold/PPI	1	2.9×	0.601
Transcription factor	1	1.4×	0.719
Other/Unknown	3	0.9×	0.758

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RNF6	Transcription factor	no		Znf_RING, Znf_RING/FYVE/PHD, RING_finger_E3_ligase
WASF3	Other/Unknown	no		WH2_dom, SCAR/WAVE_fam
PCDH15	Other/Unknown	no		Cadherin-like_dom, Cadherin-like_sf, Cadherin_CS
NEBL	Scaffold/PPI	no		Nebulin_repeat, SH3_domain, Nebulette_SH3
CDK8	Kinase	yes	2.7.11.22	Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
MIR4675	Other/Unknown	no

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	6
unknown	0

Top tissues across cohort

Tissue	Cohort genes
adrenal tissue	2
bronchial epithelial cell	1
choroid plexus epithelium	1
epithelium of nasopharynx	1
paraflocculus	1
substantia nigra pars compacta	1
substantia nigra pars reticulata	1
left adrenal gland cortex	1
male germ line stem cell (sensu Vertebrata) in testis	1
cranial nerve II	1
heart right ventricle	1
myocardium	1
buccal mucosa cell	1
secondary oocyte	1
calcaneal tendon	1
gastrocnemius	1
kidney	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RNF6	294	ubiquitous	marker	bronchial epithelial cell, epithelium of nasopharynx, choroid plexus epithelium
WASF3	271	ubiquitous	marker	substantia nigra pars compacta, substantia nigra pars reticulata, paraflocculus
PCDH15	130	tissue_specific	marker	left adrenal gland cortex, male germ line stem cell (sensu Vertebrata) in testis, adrenal tissue
NEBL	282	broad	marker	heart right ventricle, myocardium, cranial nerve II
CDK8	289	ubiquitous	yes	adrenal tissue, buccal mucosa cell, secondary oocyte
MIR4675	37		yes	calcaneal tendon, gastrocnemius, kidney

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CDK8	2,827
PCDH15	1,732
NEBL	1,384
RNF6	1,187
WASF3	1,069
MIR4675	0

Structural data

PDB: 3 · AlphaFold-only: 2 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CDK8	P49336	36
PCDH15	Q96QU1	8
NEBL	O76041	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
WASF3	Q9UPY6	66.48
RNF6	Q9Y252	49.92

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 45. Enrichment computed across 6 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Signaling by NOTCH1 PEST Domain Mutants in Cancer	1	102.0×	0.053	CDK8
Signaling by NOTCH1 in Cancer	1	102.0×	0.053	CDK8
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	1	102.0×	0.053	CDK8
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	1	92.1×	0.053	CDK8
Signaling by NOTCH1	1	89.2×	0.053	CDK8
RHO GTPases Activate WASPs and WAVEs	1	79.3×	0.053	WASF3
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	1	77.2×	0.053	CDK8
NOTCH1 Intracellular Domain Regulates Transcription	1	59.5×	0.053	CDK8
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	1	53.9×	0.053	CDK8
Sensory processing of sound by outer hair cells of the cochlea	1	51.0×	0.053	PCDH15
Signaling by TGF-beta Receptor Complex	1	50.1×	0.053	CDK8
Constitutive Signaling by NOTCH1 PEST Domain Mutants	1	49.2×	0.053	CDK8
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	1	49.2×	0.053	CDK8
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	1	49.2×	0.053	CDK8
Respiratory Syncytial Virus Infection Pathway	1	49.2×	0.053	CDK8
FCGR3A-mediated phagocytosis	1	46.8×	0.053	WASF3
Regulation of actin dynamics for phagocytic cup formation	1	46.0×	0.053	WASF3
Signaling by NOTCH	1	43.9×	0.053	CDK8
Sensory processing of sound by inner hair cells of the cochlea	1	40.8×	0.053	PCDH15
RSV-host interactions	1	39.1×	0.053	CDK8
Adipogenesis	1	39.1×	0.053	CDK8
Epigenetic regulation by WDR5-containing histone modifying complexes	1	38.6×	0.053	CDK8
Regulation of lipid metabolism by PPARalpha	1	35.2×	0.053	CDK8
VEGFA-VEGFR2 Pathway	1	34.8×	0.053	WASF3
Transcriptional regulation of white adipocyte differentiation	1	32.4×	0.055	CDK8
Signaling by TGFB family members	1	28.8×	0.059	CDK8
PPARA activates gene expression	1	23.6×	0.070	CDK8
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis	1	20.7×	0.076	CDK8
Epigenetic regulation of gene expression	1	17.8×	0.084	CDK8
Class I MHC mediated antigen processing & presentation	1	17.5×	0.084	RNF6

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cardiac muscle thin filament assembly	1	1123.5×	0.018	NEBL
equilibrioception	1	481.5×	0.018	PCDH15
positive regulation of Arp2/3 complex-mediated actin nucleation	1	421.3×	0.018	WASF3
sensory perception of light stimulus	1	374.5×	0.018	PCDH15
modification of postsynaptic actin cytoskeleton	1	280.9×	0.018	WASF3
protein K27-linked ubiquitination	1	240.7×	0.018	RNF6
regulation of androgen receptor signaling pathway	1	198.3×	0.018	RNF6
protein K6-linked ubiquitination	1	198.3×	0.018	RNF6
positive regulation of myelination	1	153.2×	0.020	WASF3
negative regulation of axon extension	1	146.5×	0.020	RNF6
oligodendrocyte development	1	120.4×	0.022	WASF3
axon extension	1	99.1×	0.023	RNF6
actin filament polymerization	1	96.3×	0.023	WASF3
lamellipodium assembly	1	88.7×	0.023	WASF3
inner ear development	1	74.9×	0.025	PCDH15
photoreceptor cell maintenance	1	71.7×	0.025	PCDH15
protein K48-linked ubiquitination	1	33.7×	0.050	RNF6
homophilic cell-cell adhesion	1	28.1×	0.057	PCDH15
cytoskeleton organization	1	26.5×	0.057	WASF3
regulation of cell shape	1	24.6×	0.058	WASF3
protein-containing complex assembly	1	22.8×	0.060	WASF3
sensory perception of sound	1	20.2×	0.064	PCDH15
actin cytoskeleton organization	1	15.8×	0.078	WASF3
ubiquitin-dependent protein catabolic process	1	14.8×	0.079	RNF6
protein ubiquitination	1	8.3×	0.133	RNF6
cell adhesion	1	7.5×	0.141	PCDH15
regulation of DNA-templated transcription	1	6.3×	0.160	RNF6
positive regulation of DNA-templated transcription	1	5.6×	0.173	RNF6
positive regulation of transcription by RNA polymerase II	1	3.0×	0.294	CDK8

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Lanreotide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Lapatinib, Temozolomide.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 5

Druggability breadth: 3 of 6 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CDK8	SORAFENIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CDK8	23	4
RNF6	0	0
WASF3	0	0
PCDH15	0	0
NEBL	0	0
MIR4675	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
SORAFENIB	4	CDK8
PONATINIB	4	CDK8
QUIZARTINIB	4	CDK8
VATALANIB	3	CDK8
DINACICLIB	3	CDK8
LINIFANIB	3	CDK8
FASUDIL	3	CDK8
ALVOCIDIB	3	CDK8
ALISERTIB	3	CDK8
LESTAURTINIB	3	CDK8
INDIRUBIN	2	CDK8
DORAMAPIMOD	2	CDK8
FORETINIB	2	CDK8
ILORASERTIB	2	CDK8
VORUCICLIB	2	CDK8
CT-7001	2	CDK8
CP-724714	2	CDK8
SENEXIN B	1	CDK8
SEL-120 FREE BASE	1	CDK8
BMS-387032	1	CDK8
SEL-120	1	CDK8
SNS-314	1	CDK8
AST-487	1	CDK8

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CDK8	509	Binding:499, Functional:10
PCDH15	9	Binding:9
WASF3	5	Binding:5

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
CDK8	2.7.11.22, 2.7.11.23	cyclin-dependent kinase, [RNA-polymerase]-subunit kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CDK8	509

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

23 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
SORAFENIB	4	CDK8
PONATINIB	4	CDK8
QUIZARTINIB	4	CDK8
VATALANIB	3	CDK8
DINACICLIB	3	CDK8
LINIFANIB	3	CDK8
FASUDIL	3	CDK8
ALVOCIDIB	3	CDK8
ALISERTIB	3	CDK8
LESTAURTINIB	3	CDK8
INDIRUBIN	2	CDK8
DORAMAPIMOD	2	CDK8
FORETINIB	2	CDK8
ILORASERTIB	2	CDK8
VORUCICLIB	2	CDK8
CT-7001	2	CDK8
CP-724714	2	CDK8
SENEXIN B	1	CDK8
SEL-120 FREE BASE	1	CDK8
BMS-387032	1	CDK8
SEL-120	1	CDK8
SNS-314	1	CDK8
AST-487	1	CDK8

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	CDK8
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	5	RNF6, WASF3, PCDH15, NEBL, MIR4675

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
RNF6	0	—
WASF3	5	—
PCDH15	9	—
NEBL	0	—
MIR4675	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 79.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	63
PHASE4	6
PHASE1	4
EARLY_PHASE1	3
PHASE3	1
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03014687	PHASE4	RECRUITING	Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
NCT04081701	PHASE4	RECRUITING	68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
NCT06679816	PHASE4	RECRUITING	Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors
NCT07034859	PHASE4	ENROLLING_BY_INVITATION	Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
NCT01371643	PHASE4	COMPLETED	Surgical Debulking of Pituitary Adenomas
NCT05822817	PHASE4	COMPLETED	Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery
NCT03271918	PHASE3	COMPLETED	Cabergoline in Nonfunctioning Pituitary Adenomas
NCT04244708	PHASE2/PHASE3	UNKNOWN	The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas
NCT00939523	PHASE2	COMPLETED	Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
NCT03465618	PHASE1	ACTIVE_NOT_RECRUITING	A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
NCT07456878	PHASE1	RECRUITING	Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
NCT03404414	PHASE1	UNKNOWN	Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT
NCT04212793	PHASE1	COMPLETED	Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
NCT07460232	EARLY_PHASE1	RECRUITING	FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
NCT07493447	EARLY_PHASE1	NOT_YET_RECRUITING	Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
NCT07568366	EARLY_PHASE1	NOT_YET_RECRUITING	AI in Endoscopic Transsphenoidal Surgery
NCT03583528	Not specified	ACTIVE_NOT_RECRUITING	DOTATOC PET/CT for Imaging NET Patients
NCT04278118	Not specified	RECRUITING	Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
NCT04569591	Not specified	RECRUITING	DDAVP for Pituitary Adenoma
NCT05254197	Not specified	RECRUITING	SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
NCT05727605	Not specified	RECRUITING	Neurocognition After Radiotherapy in CNS- and Skull-base Tumors
NCT06015802	Not specified	RECRUITING	Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
NCT06326853	Not specified	NOT_YET_RECRUITING	Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
NCT06584123	Not specified	RECRUITING	Molecular Pituitary Imaging Using 18F-FET PET
NCT06664190	Not specified	ACTIVE_NOT_RECRUITING	Pre-operative Surgical Difficulty Stratification Using Predicted Tumor Perfusion and Consistency
NCT06701838	Not specified	NOT_YET_RECRUITING	Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
NCT06831461	Not specified	RECRUITING	Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
NCT06874426	Not specified	RECRUITING	The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction
NCT06973824	Not specified	RECRUITING	A Twenty-years’ Experience in Pituitary Disease.
NCT07316101	Not specified	NOT_YET_RECRUITING	Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery
NCT07335315	Not specified	RECRUITING	Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing’s Disease Compared to Other Pituitary Tumors
NCT07446036	Not specified	ACTIVE_NOT_RECRUITING	Prediction Model for Postoperative Headache After Transsphenoidal Pituitary Surgery
NCT07595666	Not specified	ENROLLING_BY_INVITATION	Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
NCT00001452	Not specified	COMPLETED	Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
NCT00798057	Not specified	TERMINATED	Proton Radiation Therapy for Pituitary Adenoma
NCT01377701	Not specified	UNKNOWN	The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor
NCT01442220	Not specified	UNKNOWN	Genome-wide Association Study of Pituitary Tumors
NCT01465672	Not specified	COMPLETED	Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis
NCT01504399	Not specified	COMPLETED	Rhinological Outcomes in Endonasal Pituitary Surgery
NCT01556230	Not specified	COMPLETED	Prospective Study of Clinically Nonfunctioning Pituitary Adenomas

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABERGOLINE	4	3
SEVOFLURANE	4	2
AMINOLEVULINIC ACID	4	1
DESFLURANE	4	1
DESMOPRESSIN ACETATE	4	1
EDOTREOTIDE GALLIUM GA-68	4	1
SULFAMETHOXAZOLE	4	1
CHEMBL4593105	0	3
CHEMBL5192470	0	3